AHR and colitis: In a T cell–mediated colitis mice model, oral administration of IPyA, a microbiota-derived AHR agonist, decreases the frequency of IFN-γ+ IL-10- CD4+ T cells and increases that of IFN-γ- IL-10+ CD4+ T cells in the colon lamina propria.